The deal range was $19.50-$20.00. Goldman Sachs, Citi and Guggenheim acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent Biopharma announces $75M common stock, warrants offering
- ArriVent Biopharma initiated with a Buy at Clear Street
- ArriVent Biopharma price target raised to $44 from $39 at Oppenheimer
- ArriVent BioPharma Reports Positive Phase 1b Study Results
- ArriVent BioPharma’s Firmonertinib Shows Promise in NSCLC Treatment with Strong Phase 1b Results and Strategic Phase 3 Plans